Whalesbook
Bhai log, Corona Remedies mein aaj ek bada game hua hai! Bade bade institutions jaise HDFC Mutual Fund, Aberdeen, aur ADIA ne company mein **7.34%** stake kharid liya hai. Ye deal hui hai **₹777 crore** ki. Issi ke saath, ChrysCapital jaise private equity fund ne apna kuch stake bech diya hai. Shareholder base mein thoda change aa raha hai.
Aakhir hua kya?
17 June 2026 ko, Corona Remedies Limited mein National Stock Exchange (NSE) par ek dhamakedar block deal hui. Bade institutional investors ne pharma company mein 7.34% stake khareeda hai, jiska total amount lagbhag ₹777 crore hai. Shares ₹1,730 ke price par trade hue. Ye shares Sepia Investments Limited ne beche hain, jo ki private equity firm ChrysCapital se judi hui hai, aur saath mein Anchor Partners bhi the.
Kharidne wale bade players mein HDFC Mutual Fund, Aberdeen Asset Management ke alag-alag funds, Abu Dhabi Investment Authority (ADIA), Invesco Mutual Fund, Kotak Mahindra Mutual Fund, aur kai WhiteOak Capital funds shamil the.
Institutions ka confidence vs PE exit
Is deal se company ke ownership structure mein change aa raha hai. ChrysCapital jaise private equity investors ke liye ye ek planned exit ka part hota hai jahan woh apne long-term investments ko cash karte hain. Company ke December 2025 mein listing ke baad se, yeh fund dheere dheere apna stake kam kar raha hai.
Dusri taraf, bade domestic aur global institutional funds ki itni badi involvement company ke business fundamentals par trust dikhati hai. Jab bade asset managers apna paisa lagaate hain, toh yeh maan liya jaata hai ki woh company ke future growth aur market position ko lekar positive hain.
Company hai kya cheez?
Ahmedabad based Corona Remedies ek Indian pharmaceutical formulation company hai jo 2004 mein start hui thi. Yeh company women's healthcare, cardio-diabetology, pain management, aur urology jaise high-growth areas par focus karti hai. Company ke paas branded generic formulations ka ek bada portfolio hai aur ek strong distribution network bhi hai, jahan se India mein pharma market mein growth hui hai. Chronic aur acute therapeutic segments par focus karna Indian healthcare demand trends ke hisab se sahi hai, jo ki listing ke baad se company ke performance mein dikh raha hai.
Aage Investors ko kya dekhna chahiye?
Investors ko company ke profit margins par nazar rakhni chahiye, khaas kar jab woh apni manufacturing capacity badha rahe hain aur naye therapeutic areas explore kar rahe hain. Ab jab institutional base badh gaya hai, toh yeh dekhna hoga ki yeh bade funds kitna time stake hold karte hain. Iske alawa, women's healthcare jaise segments mein company ki growth aur operational costs ko manage karne ki ability bhi important hogi. Agle quarterly results aur management ka capital allocation par comment, khaas kar naye manufacturing facilities ya acquisitions mein investment ko lekar, company ke growth ke liye crucial indicators honge.
